Robert L. Ferris

Robert L. Ferris

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Robert L. Ferris

UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Oral Oncology
Verified
Journal Article
Closed access
RFRobert L. Ferris
Robert L. Ferris
GBGeorge Blumenschein
George Blumenschein
JFJerome Fayette
Jerome Fayette
JGJoel Guigay
Joel Guigay
ACA. Dimitrios Colevas
A. Dimitrios Colevas
MGMaura L. Gillison
Maura L. Gillison

11 July 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DHDonna L Herber
Donna L Herber
WCWei Cao
Wei Cao
YNYulia Nefedova
Yulia Nefedova
SNSergey V Novitskiy
Sergey V Novitskiy
SNSrinivas Nagaraj
Srinivas Nagaraj
DGDmitry Gabrilovich
Dmitry Gabrilovich
Dendritic cells in individuals with cancer and in mouse tumor models show an increase in triacylglycerides that seems to impair their antigen-processing capability and could thus contribute to tumor immune tolerance. This aberrant lipid load results from tumor-induced elevation of the scavenger receptor Msr1 on dendritic cells, and it can be targeted therapeutically to improve the efficiency of anticancer vaccines. Dendritic cells (DCs), a type of professional antigen-presenting cells, are responsible for initiation and maintenance of immune responses. Here we report that a substantial proportion of DCs in tumor-bearing mice and people with cancer have high amounts of triglycerides as compared with DCs from tumor-free mice and healthy individuals. In our studies, lipid accumulation in DCs was caused by increased uptake of extracellular lipids due to upregulation of scavenger receptor A. DCs with high lipid content were not able to effectively stimulate allogeneic T cells or present tumor-associated antigens. DCs with high and normal lipid levels did not differ in expression of major histocompatibility complex and co-stimulatory molecules. However, lipid-laden DCs had a reduced capacity to process antigens. Pharmacological normalization of lipid abundance in DCs with an inhibitor of acetyl-CoA carboxylase restored the functional activity of DCs and substantially enhanced the effects of cancer vaccines. These findings suggest that immune responses in cancer can be improved by manipulating the lipid levels in DCs.

12 June 2019 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JCJohn D. Cramer
John D. Cramer
BBBarbara Burtness
Barbara Burtness
QLQuynh Thu Le
Quynh Thu Le
RFRobert L. Ferris
Robert L. Ferris

1 January 2020 in Immunity
Verified
Journal Article
Closed access
ACAnthony R. Cillo
Anthony R. Cillo
CKCornelius H.L. Kürten
Cornelius H.L. Kürten
TTTracy Tabib
Tracy Tabib
ZQZengbiao Qi
Zengbiao Qi
SOSayali Onkar
Sayali Onkar
DVDario A.A. Vignali
Dario A.A. Vignali

1 November 2011 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
YNYuri E. Nikiforov
Yuri E. Nikiforov
NON. Paul Ohori
N. Paul Ohori
SHSteven P. Hodak
Steven P. Hodak
SCSally E. Carty
Sally E. Carty
SLShane O. LeBeau
Shane O. LeBeau
MNMarina N. Nikiforova
Marina N. Nikiforova
Context: Thyroid nodules are common in adults, but only a small fraction of them is malignant. Fine-needle aspiration (FNA) cytology provides a definitive diagnosis of benign or malignant disease in many cases, whereas about 25% of nodules are indeterminate, hindering most appropriate management. Objective: The objective of the investigation was to study the clinical utility of molecular testing of thyroid FNA samples with indeterminate cytology. Design: Residual material from 1056 consecutive thyroid FNA samples with indeterminate cytology was used for prospective molecular analysis that included the assessment of cell adequacy by a newly developed PCR assay and testing for a panel of mutations consisted of BRAF V600E, NRAS codon 61, HRAS codon 61, and KRAS codons 12/13 point mutations and RET/PTC1, RET/PTC3, and PAX8/PPARγ rearrangements. Results: The collected material was adequate for molecular analysis in 967 samples (92%), which yielded 87 mutations including 19 BRAF, 62 RAS, 1 RET/PTC, and five PAX8/PPARγ. Four hundred seventy-nine patients who contributed 513 samples underwent surgery. In specific categories of indeterminate cytology, i.e. atypia of undetermined significance/follicular lesion of undetermined significance, follicular neoplasm/suspicious for a follicular neoplasm, and suspicious for malignant cells, the detection of any mutation conferred the risk of histologic malignancy of 88, 87, and 95%, respectively. The risk of cancer in mutation-negative nodules was 6, 14, and 28%, respectively. Of 6% of cancers in mutation-negative nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology, only 2.3% were invasive and 0.5% had extrathyroidal extension. Conclusion: Molecular analysis for a panel of mutations has significant diagnostic value for all categories of indeterminate cytology and can be helpful for more effective clinical management of these patients.

15 July 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
ECEzra E. W. Cohen
Ezra E. W. Cohen
RBR. Bryan Bell
R. Bryan Bell
CBCarlo B. Bifulco
Carlo B. Bifulco
BBBarbara Burtness
Barbara Burtness
MGMaura L. Gillison
Maura L. Gillison
RFRobert L. Ferris
Robert L. Ferris
Head and neck cancers, including those of the lip and oral cavity, nasal cavity, paranasal sinuses, oropharynx, larynx and nasopharynx represent nearly 700,000 new cases and 380,000 deaths worldwide per annum, and account for over 10,000 annual deaths in the United States alone. Improvement in outcomes are needed for patients with recurrent and or metastatic squamous cell carcinoma of the head and neck (HNSCC). In 2016, the US Food and Drug Administration (FDA) granted the first immunotherapeutic approvals – the anti-PD-1 immune checkpoint inhibitors nivolumab and pembrolizumab – for the treatment of patients with recurrent squamous cell carcinoma of the head and neck (HNSCC) that is refractory to platinum-based regimens. The European Commission followed in 2017 with approval of nivolumab for treatment of the same patient population, and shortly thereafter with approval of pembrolizumab monotherapy for the treatment of recurrent or metastatic HNSCC in adults whose tumors express PD-L1 with a ≥ 50% tumor proportion score and have progressed on or after platinum-containing chemotherapy. Then in 2019, the FDA granted approval for PD-1 inhibition as first-line treatment for patients with metastatic or unresectable, recurrent HNSCC, approving pembrolizumab in combination with platinum and fluorouracil for all patients with HNSCC and pembrolizumab as a single agent for patients with HNSCC whose tumors express a PD-L1 combined positive score ≥ 1. These approvals marked the first new therapies for these patients since 2006, as well as the first immunotherapeutic approvals in this disease. In light of the introduction of these novel therapies for the treatment of patients with head and neck cancer, The Society for Immunotherapy of Cancer (SITC) formed an expert committee tasked with generating consensus recommendations for emerging immunotherapies, including appropriate patient selection, therapy sequence, response monitoring, adverse event management, and biomarker testing. These consensus guidelines serve as a foundation to assist clinicians’ understanding of the role of immunotherapies in this disease setting, and to standardize utilization across the field for patient benefit. Due to country-specific variances in approvals, availability and regulations regarding the discussed agents, this panel focused solely on FDA-approved drugs for the treatment of patients in the U.S.